Results 71 to 80 of about 113,596 (299)

Clinical Toxicities of Histone Deacetylase Inhibitors

Pharmaceuticals, 2010
The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use.
Richard L. Piekarz, John J. Wright, Susan E. Bates, Srividya Subramanian, Igor Espinoza-Delgado   +4 more
doaj   +1 more source

Acetylation and Histone Deacetylase Inhibitors in Cancer

Cellular Oncology, 2006
In recent years, the role of epigenetics in the development and treatment of cancer has gained interest and the effects of internal and external factors on the epigenetic profile are under investigation. The term “epigenetics” refers to modifications that influence phenotype without altering genotype.
Madeleine S. Q. Kortenhorst, Michael A. Carducci, Shabana Shabbeer   +2 more
doaj   +3 more sources

Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity [PDF]

, 2016
Background: Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently, different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive activities have been
Andrade, Ricardo, Arluzea, Jon, Aréchaga, Juan, De Wever, Olivier, Díaz-Núñez, María, Díez-Torre, Alejandro, Silió, Margarita   +6 more
core   +4 more sources

Deacetylase inhibitors and Histone inheritance [PDF]

, 2021
The rules governing the distribution of histones to two daughter chromatids have long been the subject of speculation. However, in Martijn Zwinderman's thesis 'Deacetylase inhibitors and histone inheritance' it becomes clear that histone distribution is inherently asymmetric.
openaire   +1 more source

Histone deacetylase inhibitors in cancer therapy [PDF]

Current Opinion in Oncology, 2008
The purpose of this review is to provide an overview of recent advances in the development of histone deacetylase inhibitors (HDACi) for the treatment of cancer.Recently, there has been a dramatic expansion of HDACi clinical investigation. There are now 11 HDACi in clinical trial, including inhibitors with a broad spectrum of HDAC isoform inhibitory ...
Min-Jung, Lee, Yeong Sang, Kim, Shivaani, Kummar, Giuseppe, Giaccone, Jane B, Trepel   +4 more
openaire   +2 more sources

Ketogenic Diet as an Epigenetic Therapy in SETD1B‐Related Epilepsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Histone lysine methyltransferases such as SETD1B regulate chromatin structure and gene transcription. Ketone bodies, including butyrate, act as histone deacetylase inhibitors. We report a 4‐year‐old boy with SETD1B‐related absence epilepsy, refractory to conventional medications, who achieved sustained > 90% seizure reduction on the Modified ...
Erica Tsang, Brian S. Gloss, Jessica P. Hayes, Andrew J. A. Holland, Manoj P. Menezes, Joceline A. Branson, Shekeeb S. Mohammad, Jingya J. Yan, Shrujna Patel, Velda X. Han, Russell C. Dale   +10 more
wiley   +1 more source

Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells [PDF]

, 2016
Cancer stem cells (CSCs) play an important role in tumor initiation, progression, therapeutic failure and tumor relapse. In this study, we evaluated the efficacy of the thiazole derivative 3-methylcyclopentylidene-[4-(4’-chlorophenyl)thiazol-2-yl ...
Buglioni, Simonetta, Carradori, Simone, DE LUCA, Teresa, De Maria, Ruggero, Del Bufalo, Donatella, Desideri, Marianna, DI MARTILE, Marta, Eramo, Adriana, Gabellini, Chiara, Mai, Antonello, Milella, MICHELE STANISLAW, Rotili, Dante, Secci, Daniela, Sette, Giovanni, Trisciuoglio, Daniela   +14 more
core   +4 more sources

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Functional characterization of Candida albicans Hos2 histone deacetylase [v3; ref status: indexed, http://f1000r.es/3xh]

F1000Research, 2014
Candida albicans is a mucosal commensal organism capable of causing superficial (oral and vaginal thrush) infections in immune normal hosts, but is a major pathogen causing systemic and mucosal infections in immunocompromised individuals.
G Karthikeyan, Maneesh Paul-Satyaseela, Nachiappan Dhatchana Moorthy, Radha Gopalaswamy, Shridhar Narayanan   +4 more
doaj   +1 more source

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source